Benzinga

DECEMBER 15, 2022

September 2022 - F. Hoffmann-La Roche Ltd. With this acquisition, the company is set to gain rights to platform technology of Good Therapeutic, which is applicable to a wide range of areas, including cancer, autoimmune diseases, metabolic disease, and pain management. Key Industry Development.

Marketability 52

Marketability Technology 52

Benzinga

MAY 30, 2022

Some factors, such as lower turn-around time, fewer needs for professional guidance, and ease of use, have encouraged prominent companies to prioritize Vitamin D Testing Market. January 2022 – F. Hoffmann-La Roche Ltd rolled out Cobas Infinity Edge for clinical settings to boost operational efficiencies and improve patient outcomes.

Marketability 40

Marketability 40

Benzinga

FEBRUARY 6, 2023

Moreover, information on the adoption of strategies such as merger and acquisition, collaboration, partnerships, and joint ventures by the companies that will drive the growth of the market has been included during the projected horizon. Get a Sample Research PDF: [link] List of Key Companies Profiled are: DuPont (U.S.)

Marketability 40

Marketability 40

Benzinga

AUGUST 10, 2022

Study to be part of Roche's Morpheus Platform designed to enable more rapid and efficient development of novel cancer immunotherapy combinations. NASDAQ: CLBS ) ("Caladrius" or the "Company") and Cend Therapeutics, Inc. ("Cend"), today announced Cend's execution of a collaboration agreement with F. BASKING RIDGE, N.J.

Alpha 40

Alpha 40